Literature DB >> 11346192

Antipsychotic-induced weight gain: a review of the literature.

D B Allison1, D E Casey.   

Abstract

With the availability of the so-called novel antipsychotic agents, extrapyramidal symptoms are becoming decreasingly problematic for patients with schizophrenia, and simultaneously, a new symptom is emerging as a preeminent concern. This side effect is weight gain and its metabolic concomitants. This article reviews what is currently known about antipsychotic-induced weight gain, describes the magnitude of the problem, briefly touches on mechanisms of action, and addresses the correlation of interindividual variations in magnitude of weight gain. In addition, we address questions about the effects of weight gain on compliance and whether or not there is a correlation between weight gain and therapeutic efficacy. Finally, we address medical consequences of weight gain and review the literature supporting various treatment options for antipsychotic-induced weight gain. As will be seen, this is an area of research in its infancy, and much work remains to be done.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11346192

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  120 in total

1.  Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.

Authors:  C D Gibson; W Karmally; D J McMahon; S L Wardlaw; J Korner
Journal:  Diabetes Obes Metab       Date:  2011-12-27       Impact factor: 6.577

Review 2.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

3.  Prevention of cardiovascular disease: obesity, diabetes and the metabolic syndrome.

Authors:  Raj S Padwal; Arya M Sharma
Journal:  Can J Cardiol       Date:  2010 Aug-Sep       Impact factor: 5.223

4.  Dietary intake of patients with schizophrenia.

Authors:  Martin Strassnig; Jaspreet Singh Brar; Rohan Ganguli
Journal:  Psychiatry (Edgmont)       Date:  2005-02

5.  Symptom control and patient adherence to treatment: key goals in the treatment of psychosis.

Authors:  Marios Adamou
Journal:  Psychiatry (Edgmont)       Date:  2004-07

6.  An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients.

Authors:  Chawanun Charnsil; Salinee Vongpanich
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-20       Impact factor: 2.570

7.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 8.  The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.

Authors:  C Cuerda; C Velasco; J Merchán-Naranjo; P García-Peris; C Arango
Journal:  Eur J Clin Nutr       Date:  2013-12-11       Impact factor: 4.016

9.  A pilot evaluation of the In SHAPE individualized health promotion intervention for adults with mental illness.

Authors:  Aricca D Van Citters; Sarah I Pratt; Kenneth Jue; Gail Williams; Patricia T Miller; Haiyi Xie; Stephen J Bartels
Journal:  Community Ment Health J       Date:  2009-12-10

10.  Exercise capacity and quality of life in patients with schizophrenia.

Authors:  Arno Kerling; Uwe Tegtbur; Marc Ziegenbein; Lena Grams; Dirk Robert Heinze; Marcel Sieberer
Journal:  Psychiatr Q       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.